Feby Savira

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2578414/publications.pdf

Version: 2024-02-01

18	240	1040056 9	996975 15
papers	citations	h-index	g-index

19	19	19	379
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. European Journal of Preventive Cardiology, 2021, 28, 975-982.	1.8	35
2	RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome. International Journal of Cardiology, 2021, 323, 260.	1.7	0
3	The Preventable Productivity Burden of Kidney Disease in Australia. Journal of the American Society of Nephrology: JASN, 2021, 32, 938-949.	6.1	6
4	RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis. International Journal of Cardiology, 2021, 326, 156.	1.7	0
5	Apoptosis signal-regulating kinase 1 inhibition reverses deleterious indoxyl sulfate-mediated endothelial effects. Life Sciences, 2021, 272, 119267.	4.3	7
6	Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells. International Journal of Biochemistry and Cell Biology, 2021, 134, 105952.	2.8	18
7	Dihydrosphingosine driven enrichment of sphingolipids attenuates TGFÎ² induced collagen synthesis in cardiac fibroblasts. IJC Heart and Vasculature, 2021, 35, 100837.	1.1	3
8	The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate. Vascular Pharmacology, 2021, 141, 106923.	2.1	4
9	Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition. Toxicology Letters, 2021, 350, 133-142.	0.8	7
10	The impact of coronary heart disease prevention on work productivity: a 10-year analysis. European Journal of Preventive Cardiology, 2021, 28, 418-425.	1.8	11
11	RE: ASK1, a new target in treating cardiorenal syndrome (CRS). International Journal of Cardiology, 2020, 316, 207.	1.7	0
12	Exogenous dihydrosphingosine 1 phosphate mediates collagen synthesis in cardiac fibroblasts through JAK/STAT signalling and regulation of TIMP1. Cellular Signalling, 2020, 72, 109629.	3.6	15
13	Cardiorenal syndrome: Multiâ€organ dysfunction involving the heart, kidney and vasculature. British Journal of Pharmacology, 2020, 177, 2906-2922.	5.4	46
14	Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome. International Journal of Cardiology, 2020, 310, 128-136.	1.7	10
15	Molecular mechanisms of protein-bound uremic toxin-mediated cardiac, renal and vascular effects: underpinning intracellular targets for cardiorenal syndrome therapy. Toxicology Letters, 2019, 308, 34-49.	0.8	12
16	The role of dihydrosphingolipids in disease. Cellular and Molecular Life Sciences, 2019, 76, 1107-1134.	5.4	31
17	Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis. Heart Lung and Circulation, 2019, 28, 495-504.	0.4	9
18	Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome. PLoS ONE, 2017, 12, e0187459.	2.5	26